Topical drug delivery to the eye: Dorzolamide

Acta Ophthalmologica

Volumn 90, Issue 7, 2012, Pages 603-608

  Loftsson, Thorsteinn ^a   Jansook, Phatsawee ^a   Stefánsson, Einar ^b  

^a UNIVERSITY OF ICELAND   (Iceland)

^b LANDSPITALI UNIVERSITY HOSPITAL   (Iceland)

Author keywords

complex; cyclodextrin; dorzolamide; drug delivery; microparticle; nanoparticle

Indexed keywords

EID: 84868200133     PISSN: 1755375X     EISSN: 17553768     Source Type: Journal    
DOI: 10.1111/j.1755-3768.2011.02299.x     Document Type: Review

References (42)

1. Afouna MI, Khedr A, &, Al-Marzoqi A, (2009): Effects of (-)-carveol and HPMC on the in vitro ocular transport and the in vivo intraocular pressure lowering effects of dorzolamide formulations in normotensive New Zealand rabbits. Drug Dev Res 70: 191-198.
2. Afouna MI, Khedr A, Abdel-Naim AB, &, Al-Marzoqi A, (2010): Influence of various concentrations of terpene-4-ol enhancer and Carbopol-934 mucoadhesive upon the in vitro ocular transport and the in vivo intraocular pressure lowering effects of dorzolamide ophthalmic formulations using albino rabbits. J Pharm Sci 99: 119-127.
3. Ammar HO, Salama HA, Ghorab M, &, Mahmoud AA, (2009): Baboemulsion as a potential ophthalmic delivery system for dorzolamide hydrochloride. AAPS PharmSciTech 10: 808-819.
4. Bansil R, &, Turner BS, (2006): Mucin structure, aggregation, physiological functions and biomedical applications. Curr Opin Colloid Interface Sci 11: 164-170. (Pubitemid 43867390)
5. Brechue WF, &, Maren TH, (1993): pH and drug ionization affects ocular pressure lowering of topical carbonic anhydrase inhibitors. Invest Ophthalmol Vis Sci 34: 2581-2587. (Pubitemid 23206489)
6. Brewster ME, &, Loftsson T, (2007): Cyclodextrins as pharmaceutical solubilizers. Adv Drug Deliv Rev 59: 645-666. (Pubitemid 47299263)
7. Chiang C-H, C-Hsieh H, D-Lu W, &, K-Kao D, (1992): Stability of topical carbonic anhydrase inhibitor 6-hydroxyethoxy-2-benzothiazole sulfonamide. J Pharm Sci 81: 299-302.
8. Conroy CW, &, Maren TH, (1995): Effect of pH on the ocular distribution of a topical carbonic anhydrase inhibitor. Exp Eye Res 61: 213-222.
9. Dahan A, Miller JM, Hoffman A, Amidon GE, &, Amidon GL, (2010): The solubility-permeability interplay in using cyclodextrins as pharmaceutical solubilizers: mechanistic modeling and application to progesterone. J Pharm Sci 99: 2739-2749.
10. Gaudana R, Jwala J, Boddu SHS, &, Mitra AK, (2009): Recent perspectives in ocular drug delivery. Pharm Res 26: 1197-1216.
11. Genead MA, Fishman GA, &, Wallia S, (2010): Efficacy of sustained topical dorzolamide therapy for cystic macular lesions in patients with X-linked retinoschisis. Arch Ophthalmol 128: 190-197.
12. Grove J, M-Quint P, &, Plazonnet B, (1990): Influence of β-cyclodextrin on intra-ocular concentrations of topical carbonic anhydrase inhibitor, L-671,152 in rabbits. In:, Duchêne D, (ed.). Minutes of the 5th International Symposium on Cyclodextrins. Paris, Editions de Santé, pp. 479-482.
13. Jansook P, &, Loftsson T, (2008): γCD/HPγCD: synergistic solubilization. Int J Pharm 363: 217-219.
14. Jansook P, Kurkov SV, &, Loftsson T, (2010a): Cyclodextrins as solubilizers: formation of complex aggregates. J Pharm Sci 99: 719-729.
15. Jansook P, Moya-Ortega MD, &, Loftsson T, (2010b): Effect of self-aggregation of γ-cyclodextrin on drug solubilization. J Incl Phenom Macrocycl Chem 68: 229-236.
16. Jansook P, Stefánsson E, Thorsteinsdõttir M, Sigurdsson BB, Kristjánsdõttir SS, Bas JF, Sigurdsson HH, &, Loftsson T, (2010c): Cyclodextrin solubilization of carbonic anhydrase inhibitor drugs: formulation of dorzolamide eye drop microparticle suspension. Eur J Pharm Biopharm 76: 208-214.
17. Kristinsson JK, Friðriksdõttir H, Thõrisdõ ttir S, Sigurðardõttir AM, Stefánsson E, &, Loftsson T, (1996): Dexamethasone-cyclodextrin-polymer co-complexes in aqueous eye drops. Invest Ophthalmol Vis Sci 37: 1199-1203.
18. Lai SK, O'Hanlon DE, Harrold S, Man ST, Y-Wang Y, Cone R, &, Hanes J, (2007): Rapid transport of large polymeric nanoparticles in fresh undiluted human mucus. Proc Natl Acad Sci U S A 104: 1482-1487. (Pubitemid 46214616)
19. Loftsson T, (2002): Cyclodextrins and the biopharmaceutics classification system of drugs. J Incl Phenom Macrocycl Chem 44: 63-67. (Pubitemid 38075665)
20. Loftsson T, &, Brewster ME, (1996): Pharmaceutical applications of cyclodextrins. 1 Drug solubilization and stabilization. J Pharm Sci 85: 1017-1025. (Pubitemid 26338912)
21. Loftsson T, &, Brewster ME, (2010): Pharmaceutical applications of cyclodextrins: basic science and product development. J Pharm Pharmacol 62: 1607-1621.
22. Loftsson T, &, Duchêne D, (2007): Cyclodextrins and their pharmaceutical applications. Int J Pharm 329: 1-11. (Pubitemid 44937538)
23. Loftsson T, &, Stefánsson E, (2007): Cyclodextrins in ocular drug delivery. J Drug Deliv Sci Tech 17: 3-9.
24. Loftsson T, Friariksdottir H, Stefánsson E, Thõrisdõ ttir S, Ã Guamundsson, &, Sigthõrsson T, (1994): Topically effective ocular hypertensive acetazolamide and ethoxyzolamide formulations in rabbits. J Pharm Pharmacol 46: 503-504. (Pubitemid 24179546)
25. Loftsson T, Brewster ME, &, Másson M, (2004): Role of cyclodextrins in improving oral drug delivery. Am J Drug Deliv 2: 261-275. (Pubitemid 40045491)
26. Loftsson T, Vogensen SB, Brewster ME, &, Konráasdõttir F, (2007): Effects of cyclodextrins on drug delivery through biological membranes. J Pharm Sci 96: 2532-2546. (Pubitemid 47597809)
27. Loftsson T, Sigurasson HH, Konráasdõttir F, Gísladõttir S, Jansook P, &, Stefánsson E, (2008): Topical drug delivery to the posterior segment of the eye: anatomical and physiological considerations. Pharmazie 63: 171-179. (Pubitemid 351449926)
28. Maren TH, (1995): The development of topical carbonic anhydrase inhibitors. J Glaucoma 4: 49-62.
29. Maren TH, Bar-Ilan A, Conroy CW, &, Brechue WF, (1990): Chemical and pharmacological properties of MK-927 a sulfonamide carbonic anhydrase inhibitor that lowers intraocular pressure by the topical route. Exp Eye Res 50: 27-36. (Pubitemid 20058620)
30. ® (Dorzolamide Hydrochloride Ophthalmic Solution), Package Insert. Merck & Co.
31. Merkus FWHM, Verhoef JC, Marttin E, Romeijn SG, van der Kuy PHM, Hermens WAJJ, &, Schipper NGM, (1999): Cyclodextrin in nasal drug delivery. Adv Drug Deliv Rev 36: 41-57.
32. Messner M, Kurkov SV, Jansook P, &, Loftsson T, (2010): Self-assembled cyclodextrin aggregates and nanoparticles. Int J Pharm 387: 199-208.
33. Munro IC, Newberne PM, Young RR, &, Bär A, (2004): Safety assessment of γ-cyclodextrin. Regul Toxicol Pharmacol 39 (Suppl. 1): S3-S13.
34. Pfeiffer N, (1994): The potential for topical carbomic anhydrase inhibitors in glaucoma therapy. Curr Opin Ophthalmol 5: 20-25. (Pubitemid 24178228)
35. Schipper NGM, Hermens WAJJ, Romeyn SG, Verhoef J, &, Merkus FWHM, (1990): Nasal absorption of 17-β-estradiol and progesterone from dimethyl-cyclodextrin inclusion formulation in rats. Int J Pharm 64: 61-66.
36. Schoenwald RD, &, Ward R, (1978): Relationship between steroid permeability across excited rabbit cornea and octanol-water partition coefficients. J Pharm Sci 67: 786-788. (Pubitemid 8355235)
37. Seong GJ, Lee SC, Lee JH, Chu YK, &, Hong YJ, (2001): Comparisons of intraocular-pressure-lowering efficacy and side effects of 2% dorzolamide and 1% brinzolamide. Ophthalmologica 215: 188-191. (Pubitemid 32525977)
38. Shirasaki Y, (2008): Molecular design for enhancement of ocular penetration. J Pharm Sci 97: 2462-2596.
39. Sigurdsson HH, Stefánsson E, Gudmundsdõttir E, Eysteinsson T, Thorsteinsdõttir M, &, Loftsson T, (2005): Cyclodextrin formulation of dorzolamide and its distribution in the eye after topical administration. J Control Rel 102: 255-262. (Pubitemid 40093790)
40. Sugrue MF, (1989): The pharmacology of antiglaucoma drugs. Pharm Ther 43: 91-138. (Pubitemid 19199089)
41. Vargas F, Hisbeth MV, &, Rojas JK, (1998): Photolysis and photosensitized degradation of the diuretic drug acetazolamide. J Photochem Photobiol A Chem 118: 19-23. (Pubitemid 128340193)
42. Worakul N, &, Robinson JR, (2008): Ocular pharmacokinetics/ pharmacodynamics. Eur J Pharm Biopharm 44: 71-83.